Invivogen

Cayla

Centre National De La Recherche Scientifique

Université Paul Sabatier (toulouse Iii)

Centre Hospitalier Universitaire De Toulouse

Institut National De La Sante Et De La Recherche Medicale

Daniel Drocourt

Gerard Tiraby

Fabienne Vernejoul

Thierry Lioux

Eric Perouzel

Gilles Etienne

Elise Armau

Arnaud Debin

Antoine Blancher

Gérard Tiraby

Nicolas Congy

Jean Paul Reynes

Jean-Gerard Tiraby

Christophe Cazaux

Louis Buscail

Michèle Tiraby

Jean-Paul Reynes

Christiane Susini

Céline Casteran

A method for determining the quantity of anti-HLA antibodies of a liquid medium containing antibodies.

Anti-HLA monoclonal chimeric immunoglobulin, method and kit implementing such a monoclonal chimeric immunoglobulin

A monoclonal chimeric immunoglobulin wherein the heavy chains and the light chains are human by nature in their constant parts, in particular, the heavy chain constant parts are chosen from the group formed of the heavy chain constant parts of an IgA, of an IgG or of an IgM and the light chain constant parts are chosen from the group formed of the kappa chains and the lambda chains, and the light chain and the heavy chain variable parts are chosen from the group formed of monoclonal antibodies specific to monomorphic epitopes of HLA class I antigens and monoclonal antibodies specific to monomorphic epitopes of HLA class II antigens. A process for standardization of the screening and for quantification of anti-HLA antibodies in a liquid medium is also described.

Anti-HLA monoclonal chimeric immunoglobulin, process and kit employing such a monoclonal chimeric immunoglobulin

A conjugated compound of formula Q-Z&#x2014;Rwherein Q is a TLR7 and/or TLR8 agonist and Z&#x2014;Ris a TLR2 agonist, and the uses thereof in the treatment of infection, cancer or immune disorders or for use in vaccines.

Conjugated TLR7 and/or TLR8 and TLR2 agonists

A conjugated compound of formula Q-Z&#x2014;Rwherein Q is a TLR7 and/or TLR8 agonist and Z&#x2014;Ris a lipid covalently linked to an amino acid or peptide coupled to a polyamine group, and a process for the manufacture of the conjugated compound, as well as a complex formed between the conjugated compound and a polyanionic molecule and a pharmaceutical composition containing the conjugated compound or complex. Also described is the use of the conjugated compound or complex in the treatment of infection, cancer or immune disorders or for use in vaccines.

Compositions of TLR7 and/or TLR8 agonists conjugated to lipids

The present invention concerns products containing (i) at least one nucleic acid sequence coding for the human somatostatin 2 receptor protein (sst2) having the sequence SEQ ID NO: 1, ortholog or derivative thereof, (ii) at least one nucleic acid sequence coding for the human deoxycytidine kinase protein (dck) having the sequence SEQ ID NO:2, ortholog or derivative thereof, (iii) at least one nucleic acid sequence coding for the human uridine monophosphate kinase protein (umk) having the sequence SEQ ID NO: 3 ortholog or derivative thereof, and (iv) gemcitabine, as a combined preparation for simultaneous, separate, or sequential use for treating cancer in a subject.

Somatostatin 2 receptor (sst2), deoxycytidine kinase (dck) and uridine monophosphate kinase (umk) pancreatic gene therapy

A conjugated compound of Formula I: Q-Z&#x2014;Rwherein Q is a TLR7 and/or TLR8 agonist and Z&#x2014;Ris a TLR2 agonist, the conjugated compound being chosen among compounds of Formula II: 

Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists

A synthetic gene devoid of CpG nucleotide derived by genetic engineering from copepod luciferases genes that code for a new secreted luciferase with a strong bioluminescent signal. This gene display advantageous properties to be used as a reporter genes in cell based assays.

CPG-free gene for a new secreted reporter protein

The invention relates to a new series of bacterial plasmid vectors which are fully devoid of CpG and which can express synthetic genes which do not contain CpG in the bacteria

Synthetic genes and bacterial plasmids devoid of CpG

The present invention relates to two groups of suicide hybrid genes in which genes from one group specifically activate the pyrimidine nucleobase analog 5-fluorocytosine and genes from the other group activate the pyrimidine nucleoside analog azidothymidine to derivatives toxic for mammalian cells.The present invention further relates to methods for the selective killing of transfected tumor cells or immune cells using a single suicide hybrid gene or the combination of two suicide hybrid genes selected for a complementarity in their antimetabolic action. The present invention also relates to eukaryotic vectors comprising two expression suicide gene units, the first permitting the sensitization of tumor cells to 5-fluorocytosine and the second permitting the sensitization of HIV-infected cells to Azidothymidine in a synergistic fashion.

Suicide genes and new associations of pyrimidine nucleobase and

A method of transforming eukaryotic or prokaryotic hosts sensitive to an antibiotic of the phleomycin family to confer resistance to the antibiotic is disclosed in which a phleomycin resistance gene is used as a selectable marker.

Growing community of inventors

Saint Orens de Gameville, France

Daniel Drocourt